A survey of consultant members of the British Association of Oral and Maxillofacial Surgeons regarding bisphosphonate-induced osteonecrosis of the jaws

British Journal of Oral and Maxillofacial Surgery

Volumn 47, Issue 8, 2009, Pages 598-601

  Rogers, S N ^a,b   Hung, J ^a   Barber, A J ^a   Lowe, D ^a,b  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b EDGE HILL UNIVERSITY   (United Kingdom)

Author keywords

Bisphosphonate induced osteonecrosis of the jaws; Bisphosphonates; British Association of Oral and Maxillofacial Surgeons; Survey

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE; METRONIDAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMORBIDITY; CONSULTATION; DIABETES MELLITUS; DRUG INDICATION; DRUG WITHDRAWAL; HUMAN; INFECTION; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MAXILLOFACIAL SURGERY; MEDICAL SOCIETY; MOLAR TOOTH; MOUTH HYGIENE; ORAL SURGERY; PREOPERATIVE CARE; PRESCRIPTION; QUESTIONNAIRE; STEROID THERAPY; SURGEON; TOOTH EXTRACTION; TREATMENT DURATION; UNITED KINGDOM;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS, LOCAL; ANTIBIOTIC PROPHYLAXIS; ATTITUDE OF HEALTH PERSONNEL; BONE DENSITY CONSERVATION AGENTS; CHLORHEXIDINE; DENTAL SERVICE, HOSPITAL; DENTIST'S PRACTICE PATTERNS; DIPHOSPHONATES; GREAT BRITAIN; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; MASS SCREENING; MOLAR; OSTEONECROSIS; QUESTIONNAIRES; SOCIETIES, DENTAL; SURGERY, ORAL; TIME FACTORS; TOOTH EXTRACTION; TOOTH SOCKET; WOUND HEALING;

EID: 71949092358     PISSN: 02664356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjoms.2009.07.020     Document Type: Article

References (24)

1. Cheng A., Mavrokokki A., Carter G., Stein B., Fazzalari N.L., Wilson D.F., et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 50 4 Suppl. 2 (2005) S4-S13
2. Marketos M. The top 200 brand drugs in 2003 (by units). Drug Topics 148 (2004) 76
3. National Institute for Clinical Excellence. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal guidance 87 (2005), NICE, London
4. Walter C., Al-Nawas B., Grötz K.A., Thomas C., Thüroff J.W., Zinser V., et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54 (2008) 1066-1072
5. Ross J.R., Saunders Y., Edmonds P.M., Patel S., Broadley K.E., and Johnston S.R. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327 (2003) 469 Erratum in: BMJ 2004; 328:384
6. Badros A., Terpos E., Katodritou E., Goloubeva O., Kastritis E., Verrou E., et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 26 (2008) 5904-5909
7. Boonyapakorn T., Schirmer I., Reichart P.A., Sturm I., and Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44 (2008) 857-869
8. Fehm T., Beck V., Banys M., Lipp H.P., Hairass M., Reinert S., et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112 (2009) 605-609
9. Russell R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 119 Suppl. 2 (2007) S150-S162
10. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
11. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
12. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
13. Silverman S.L., and Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 122 2 Suppl. (2009) S33-45
14. Novince C.M., Ward B.B., and McCauley L.K. Osteonecrosis of the jaw: an update and review of recommendations. Cells Tissues Organs 189 (2009) 275-283
15. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 (2008) 826-836
16. Mavrokokki T., Cheng A., Stein B., and Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415-423
17. Sedghizadeh P.P., Stanley K., Caligiuri M., Hofkes S., Lowry B., and Shuler C.F. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 140 (2009) 61-66
18. Khan A.A., Sándor G.K., Dore E., Morrison A.D., Alsahli M., Amin F., et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35 (2008) 1391-1397 Erratum in: J Rheumatol 2008; 35:1688. J Rheumatol 2008; 35:2084
19. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369-376
20. Malden N., Beltes C., and Lopes V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J 206 (2009) 93-98
21. Abu-Id M.H., Warnke P.H., Gottschalk J., Springer I., Wiltfang J., Acil Y., et al. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36 (2008) 95-103
22. Grewal V.S., and Fayans E.P. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management. NY State Dent J 74 (2008) 38-44
23. Ruggiero S.L., and Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med 60 (2009) 85-96
24. McLeod MN, Bater MC, Brennan PA. Management of patients at risk of osteoradionecrosis: questionnaire survey of practice in the United Kingdom, and suggestions for best practice. Br J Oral Maxillofac Surg 2009 Aug 4, [Epub ahead of print].